Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019

For the 38th prioritisation (January 2019), ten drugs were filtered out of 502 identified and were sent to prioritisation. Of these, three drugs were ranked as 'highly relevant' by the expert panel, seven as 'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document